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Background: Tuberculosis (TB) and HIV co-infection remains a major public health problem. In spite of different
initiatives implemented to tackle the disease, many countries have not reached TB control targets. One of the major
attributing reasons for this failure is infection with HIV. This study aims to determine the effect of HIV infection on
the survival of TB patients.
Findings: A retrospective cohort study was employed to compare the survival between HIV positive and HIV
negative TB patients (370 each) during an eight month directly observed treatment short-course (DOTS)
period. TB patient’s HIV status was considered as an exposure and follow up time until death was taken as
an outcome. All patients with TB treatment outcomes other than death were censored, and death was
considered as failure. Cox proportional hazard regression model was used to determine the hazard ratio
(HR) of death for each main baseline predictor. TB/HIV co-infected patients were more likely to die;
adjusted Hazard Rate (AHR) =1.6, 95%CI (1.01, 2.6) during the DOTS period. This risk was statistically higher
among HIV patients during the continuation phase (p=0.0003), as a result HIV positive TB patients had
shorter survival (Log rank test= 6.90, df= 2, p= 0.008). The adjusted survival probability was lower in
HIV positive TB patients (< 15%) than HIV negative TB patients (> 85%) at the end of the DOTS period
(8th month).
Conclusion: TB treatment survival was substantially lower in HIV infected TB patients, especially during the
continuation phase. Targeted and comprehensive management of TB/HIV with a strict follow up should be
considered through the entire TB treatment period.
Keywords: TB treatment, Survival, TB patients, HIV positive, Hawassa, Health centerFindings
Background
Tuberculosis and HIV co-infection remains a major
public health challenge throughout the world. An extra
25% of deaths among TB patients is attributable to
co-infection with HIV according to the WHO 2009
TB report [1]. TB is often the first opportunistic* Correspondence: debebesh@gmail.com
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distribution, and reproduction in any mediuminfection and a leading cause of death in HIV infected
persons [2-4].
HIV infection is the primary reason for the failure to
meet tuberculosis control targets (at least 85% cure rate
among new sputum smear positive TB cases) [5] in
countries with high HIV infection [6]. This is attributable
to factors such as over diagnosis of sputum smear-
negative TB, under diagnosis of sputum smear-positive
TB, low cure rates, high morbidity, mortality and default
rates during treatment [6,7], and atypical clinical presenta-
tion of TB in HIV infected patients [8]. Consequently,
HIV-infection leads to diagnostic challenges and delays inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[8]. Ethiopia ranks seventh among the world’s 22 high-
burden TB countries [9,10].
In Ethiopia in 2007, TB was the cause of 76,000
deaths, of which 30% were among HIV positive patients
[1,9]. HIV infected people are more likely to have severe
forms of TB (disseminated and extra-pulmonary), as a
consequence of which TB is the leading cause of mortal-
ity and morbidity in HIV infected people, with up to one
in three dying from TB [11].
Many studies and reports elsewhere have demonstrated
a high TB treatment death rate in TB/HIV co-infected
patients when compared to HIV negative TB patients
[1,12], as high as 35%.
The goal of TB/HIV collaborative activities is to
reduce mortality, default and relapse, and to prevent
drug resistance [5,6,13,14]. Only few studies showed the
critical time of death, but with questionable power [15].
The present study assessed the impact of HIV infection
on the survival of TB patients during the period of
DOTS in southern Ethiopia.
Methods
This study was conducted in February 2010 to deter-
mine the impact of HIV infection on the survival of TB
patients treated from 2006–2010 in Hawassa Health
Center (HHC) which is located in Hawassa, the capital
city of the Southern Nations Nationalities and Peoples
Region (SNNPR) of Ethiopia.
As per the national guidelines for management of TB
[5], patients with symptoms suggestive of pulmonary TB
submit three (spot, morning, spot) sputum samples. If at
least two smear results were positive, a patient was
regarded as smear positive. Since errors made during
handling of the specimen can never be excluded, only
one positive smear result in HIV negative patient does
not confirm diagnosis of TB. Therefore, diagnosis of
smear positive pulmonary TB in patients with only one
positive smear result was supported by radiologic abnor-
malities consistent with active pulmonary tuberculosis.
In HIV positive patients, one positive smear result was
necessary to make diagnosis of smear positive pulmon-
ary TB. Similarly, a patient who had negative smear
results and showed no progress following treatment with
non-specific broad-spectrum antibiotics (excluding anti-TB
drugs) for suspected bacterial infection was categorized as
having smear negative pulmonary TB.
Extra-pulmonary tuberculosis (EPTB) was not diagnosed
in the health center but in hospitals clinically by decision
of the clinicians. Patients with visible external masses were
requested to have biopsy tests.
Patients diagnosed with TB were referred to TB clinics
to receive an HIV test and be registered for DOTS. A
TB patient who comes to the TB clinic for treatmentundergoes a process called provider initiated HIV coun-
seling and testing, where the TB care provider counsels
the patient for HIV test. A rapid test algorithm is used
to determine HIV infection. The patient’s HIV status
and other relevant information including treatment
outcome were recorded on the TB log book prescribed
by the Ministry of Health of Ethiopia.
Smear positive patients registered in the DOTS clinic
receive 8 months short course chemotherapy: daily
supervised ethambutol, rifampicin, isoniazid and pyrazi-
namide (ERHZ) combination for 2 months followed by
self-administered ethambutol and isoniazid (EH). Smear
negative and EPTB patients receive rifampicin, isoniazid
and pyrazinamide (RHZ) during the intensive phase and
EH during the continuation phase. According to the
national TB treatment guideline, new smear positive
cases, seriously ill smear negative cases and seriously ill
new EPTB cases were placed under TB treatment
category one; whereas new smear negative and new
EPTB cases who were not seriously ill were treated
under TB treatment category three [5].
Before data collection, two independent sampling
frames were developed by taking HIV status of TB
patients as a stratifying variable. The sampling frame for
HIV positive stratum constituted 420 TB patients and
that for HIV negative stratum constituted 1,350 TB
patients registered during the study period. This retro-
spective cohort study compared TB treatment survival
during an eight month DOT period between 370 HIV
positive and 370 HIV negative TB patients randomly
selected from each sampling frame using a computer
generated random numbers.
Survival time was months from the date of initial diag-
nosis of TB to death while in TB treatment or, in the
case of individuals who did not die, the last follow-up
recorded by the health center. Whereas individuals who
died were considered as failures, those who remained
alive until the end of the treatment or dropped out of
treatment were considered as censored.
The sample size was determined by setting type one
error at 5%, power at 80% and the exposed to non-
exposed ratio at 1.0. The findings of related studies were
also considered in determining sample size [1,12,16].
Data were abstracted using checklists developed by the
investigators. To minimize data entry errors EPI Info
version 3.3.2 was used. Data were analyzed using Stata
version 9.2.
P values < 0.05 and confidence level of 95% were con-
sidered to indicate statistical significance. Cox propor-
tional hazard regression model was used to determine
the hazard ratio (HR) of death for each main baseline
predictor. To assess the association between baseline
variables and mortality, two strategies were used. First,
each baseline variable that did not violate assumptions
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model. Second, a multivariate Cox proportional hazards
model was fitted with the predictors that have P ≤ 0.3 in
the bivariate model. Eventually only those variables that
remained significant at p ≤ 0.05 in the final model were
retained as independent predictors of survival. Life table
survival analysis was used to estimate DOT survival
probability of TB patients. Kaplan Meier analysis was
also used to estimate graphically the survival probabilities.
The observed difference in survival time between HIV
positive and HIV negative TB patients was compared using
the log rank test. Violation of proportional hazard assump-
tions was checked by procedures: Log (−log (st) plots,
Schoenfeld residual plots and by regressing Schoenfeld
residuals against time to test for independence between
time and residuals. Incidence rates with person-months
and cumulative incidence were calculated for death as TB
treatment outcome.
The study protocol was approved by the Institutional
Review Board (IRB) of Addis Ababa University, College
of Health Sciences.
Results
Description of the cohort
Among TB patients registered for the DOT program
from 2006 –2010, the data of 740 (370 HIV positive and
370 HIV negative) patients were retrieved from the TB
logbook for the study. Nearly all of the study subjects;
99.2% of HIV positive and 96.2% of HIV negative TB
patients were from urban areas. The median and inter
quartile range(IQR) for the age of HIV positive TB
patients were 30 and 25–36 years respectively while the
corresponding values for HIV negative study subjects
were 25 and 20–36 years. Males were predominant in
both groups especially among HIV negative TB patients;
189 (51.1%) in HIV positives and 228 (61.6%) in HIV
negatives. Equal proportions of TB patients were treated
for TB as new cases in both HIV positive 351 (94.9%)
and negative 345 (93.2%) study cohorts.
A higher proportion of HIV positive 351 (94.9%) than
negative 322 (87%) TB patients were treated as WHO
TB treatment category one. But a lower proportion of
HIV positive 4 (1.1%) than negative 25 (6.8%) TB
patients were treated as WHO TB treatment category
three.
Among HIV positive TB patients, 124 (33.24%) were
known to have started cotrimoxazole prophylactic
therapy (CPT). Regarding anti retroviral treatment
(ART) initiation, out of 370 HIV positive TB patients; 52
(14.1%) were known to have started, 39 (10.5%) were
known not to have started, and the rest 279 (75.4%) had
no known history of ART initiation. Information on
marital status was recorded for only 130 (35.1%) HIV
positive patients, of whom 56 (43.1%) were single.Similarly, of 225 (60.8%) HIV negative TB patients with
recorded marital status, 138 (61.3%) were single.
Regarding TB type, 21.6% of HIV positive and 47% of
HIV negative TB patients had smear positive pulmonary
TB (Table 1).
Time of occurrence for death
A total of 78 deaths occurred during the TB treatment
period. Most of the deaths 46 (58.9%) [24 in HIV positive
and 22 in HIV negative] occurred during the intensive
phase of treatment. The majority of deaths 50 (64%)
occurred in HIV positive TB patients. In accord with the
above finding, the mean and median time of death for
those who died in the intensive phase was 27.9 and 29
days respectively.
Concerning the association between HIV status and
risk of death during the intensive phase, the risk does
not significantly differ between HIV positive and HIV
negative TB patients (p=0.15). Unlike the situation
during the intensive phase, the risk was higher among
HIV positive TB patients during the continuation phase,
7.5 per 1000 (26 of 346) compared to HIV negative TB
patients 1.7 per 1000 (6 of 348) (p=0.0003). The inci-
dence rate of death among HIV positive study subjects
was 20.6 per 1000 person months of follow up (50 died
in a 2430.2 months of follow up) whereas the rate was
10.8 per 1000 person months of follow up (28 died in a
2582.6 months of follow up) among HIV negative TB
patients. If one is HIV positive and on TB treatment the
risk of death was 2 times higher than for an HIV nega-
tive patient on TB treatment: RR (95%CI) 1.9[1.2- 3.1].
Almost half of the deaths among HIV positive TB
patients were attributable to HIV infection: AR% (95%
CI) 47.3[14.7-68.1]. The PAR% was 30.3%.
Survival status of the study subjects
Of 370 HIV positive and 370 HIV negative TB patients
followed for 8 months, 50 (13.5%) of the HIV positive
and 28 (7.6%) of the HIV negative died and were treated
as failure in the analysis. The remaining 320 (86.5%)
HIV positive and 342 (92.4%) HIV negative patients
became censored during the follow up period. The mini-
mum follow up period was 1 and 3 days in HIV positive
and HIV negative TB patients respectively, with the
maximum being 8 months for both groups. The majority
of deaths, 46 (58.97%) occurred in the intensive phase
(the first 2 months) of treatment, whereas the rest of the
deaths, 32 (41.03%), occurred during the continuation
phase (6 months).
Life table analysis was used to estimate the survival
probabilities of TB patients. The rate of survival at the end
of the intensive phase was the same in HIV positive and
HIV negative TB patients (93.7% and 94.0%, respectively).
After the intensive phase, the survival rate in HIV positive
Table 1 Baseline characteristics of TB patients treated in
Hawassa health center from 2006–10






Urban 367(99.2) 356(96.2) 723(97.7)
Rural 3(0.8) 14(3.8) 17(2.3)
Sex
Male 189(51.1) 228(61.6) 417(56.4)
Female 181(48.9) 142(38.4) 323(43.6)
Age (years)
15- 20 39(10.5) 101(27.3) 140(18.9)
21-40 279(75.4) 197(53.2) 476(64.3)
41-60 48(13) 58(15.7) 106(14.3)
60-90 4(1.1) 14(3.8) 18(2.4)
Marital Status (n=355)
Single 56(43.1) 138(61.3) 194(54.6)
Married 64(49.2) 84(37.3) 148(41.7)
Divorced 9(6.9) 2(0.9) 119(33.5)
Widowed 1(0.8) 1(0.5) 2(0.6)
no mention 240(64.9) 145(39.2) 385(52)
Case definition
New 351(94.9) 345(93.2) 696(94)
Relapse 17(5) 22(6) 39(5.3)
Return after
default
2 (0.5) 10.3) 3(0.4)
Failure 0 2(0.5) 2(0.3)
TB Type




EPTB 56(15.1) 78(21.1) 134(18.1)
Rx Category
I 351(94.9) 322(87) 673(91)
II 15(4.1) 23(6.2) 38(5.1)





Hospital 88(23.8) 103(27.8) 191(25.8)




No mention 237(64.1) 237(64.1)
Table 1 Baseline characteristics of TB patients treated in




No mention 279(75.4) 279(75.4)
CPT= Cotrimoxazole, ART=Antiretroviral Therapy.
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months of treatment, and then remained at 85.7% until all
patients become censored at month eight. But in HIV
negative TB patients, at the end of the 8th month, by
which time all patients were censored, the survival rate
was 92.2%, (Table 2).
In agreement with the life table estimation, the Kaplan
Meier survival curve (Figure 1) showed statistically
lower survival in HIV positive TB patients (log rank
statistic= 6.90, df= 2, P= 0.0086).
In the adjusted survival curve (adjusted to baseline
characteristics in table one), the survival rate of HIV
negative TB patients was > 85% at the end of eighth month.
But for HIV positive TB patients, the median survival was
at about the end of intensive phase, and dropped to < 15%
at the end of the study period (8th month) where all the
remaining TB patients become censored (Figure 2).
Factors affecting the survival of TB patients on DOTs
The relationship between the main baseline variables and
the risk of death was analyzed using a Cox proportional
hazard regression model. Before fitting the covariates into
the model, proportional hazard assumption were checked
by plotting “Schoenfeld residuals, regressing Schoenfeld
residuals against time to test for independence between
time and residuals and by examining log (log (st) plots.
The covariates which violated the assumptions were not
included in the Cox model. The result showed that age,
weight, smear negative pulmonary TB, dose of anti TB
drugs, and HIV status were all significantly associated with
death of TB patients during the period of DOT (Table 3).
Compared to HIV negative patients, the HR of dying
from TB increased significantly by 60% in HIV positive
TB patients on DOTS; AHR = 1.6, 95% CI: [1.01, 2.6].
Mortality risk among TB patients increases by about 3%
for every year increase in age; AHR =1.03, 95% CI:
[1.02,1.05]. Accordingly, for every five and 10 years
increase in age, the risk of death increases by 15.9% and
34.4% respectively. However, mortality risk decreases by
about 6% for every kilogram (kg) increase in weight.
This risk further decreases by 26.6% for every five kg
increase in weight (Table 4).
A multivariate Cox proportional hazard adjusted
model was fitted with variables having a p-value < 0.3 in
the bivariate Cox proportional model. However, cases
Table 2 Survival of TB patients by HIV status, Hawassa health center 2006–2010
HIV Positive HIV Negative
Interval (month) N Death Censored Survival N Death Censored Survival
(0–1) 370 10 7 0.9727 370 13 5 0.9646
(1–2) 353 13 7 0.9365 352 9 8 0.9397
(2–3) 333 10 6 0.9082 335 1 4 0.9369
(3–4) 317 5 8 0.8936 330 1 7 0.934
(4–5) 304 8 14 0.8696 322 2 7 0.9281
(5–6) 282 2 9 0.8633 313 2 6 0.9221
(6–7) 271 2 3 0.8569 305 0 7 0.9221
(7–8) 266 0 1 0.8569 298 0 2 0.9221
(8–9) 265 0 265 0.8569 296 0 296 0.9221
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analysis. In addition, the smear result at baseline was
dropped because of its colinearity with other predictors.
In the final model, variables with a p-value less than 0.05
were retained as independent predictors of death.
Accordingly, only three covariates, namely being HIV
positive, age, and baseline weight remained as independent
predictors of death (Table 4).
Discussion
Death caused by TB is preventable. Management can be
modified at the time of highest risk for death if known.
Many researchers outside Ethiopia have discussed higher
TB mortality in HIV positive TB patients. Ethiopia does
have no such data [1], yet the TB/HIV co- infection is
among the highest in Africa. This study has discussed
the effect of HIV infection on the survival of TB patients
during DOTS period in Ethiopia by comparing survival
difference between HIV positive and negative TB
patients using a power of 87%. Similarly, the study has
demonstrated significant difference on the time of death
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Survival Probabilities of TB patients by HIV status
Log rank test= 6.90, df= 2,P= 0.008
Figure 1 Survival probabilities by HIV status of TB patients
treated in Hawassa health center, 2006-2010.Similar to the current study, numbers of studies
[14,17] have reported higher overall death rates among
HIV-positive TB patients; as high as four times increased
risk of death in a previous report during TB treatment.
In this study, almost half of the deaths in HIV positive
TB patients were attributed to their HIV infection. If
HIV positive TB patients had not been infected by HIV,
almost 50% of the observed deaths would not have
occurred.
Information about the time of death among TB
patients while on treatment could help provide the ne-
cessary care timely. In the current study, irrespective of
one’s HIV status, most of the deaths occurred during
the intensive phase. This may suggest that late presen-
tation was a major factor for early death than HIV in-
fection itself.
Unlike another study elsewhere [15], risk of death was
not different in the intensive phase between HIV posi-
tive and negative TB patients, but significantly higher
among the HIV positive TB patients during the continu-
ation phase. This finding may suggest the self supervised















0 2 4 6 8
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Adjusted Survival Curve of TB Patients by HIV status
Figure 2 Adjusted survival curve of the study subjects by HIV
status, Hawassa Health Center, 2010.
Table 3 Univariate predictors of death among TB patients on DOTs in Hawassa health center, 2006–10
Covariates Number at risk Number of death Crude hazard ratio 95% CI P-value
Urban 723 75 1
Rural 17 3 1.9 (0.59,5.9) 0.28
Gender
Male 417 43 1
Female 323 35 1.03 (0.66-1.6) 0.14
Age(years) 740 78 1.028 (1.01,1.04) 0.000
Weight(kg) 740 78 .944 (0.92, .97) 0.000
Marital Status(n=342)
Single 194 16 1
Married 148 22 1.9 (0.99,3.6) 0.053
Center TB Diagnosed
Health Center 549 59 1
Hospital 191 19 0.92 (0.55,1.54) 0.74
TB treatment history
New 696 73 1
Re-treatment 44 5 1.1 (0.43,2.6) 0.9
Treatment Category
I 673 72 1
II 38 4 0.97 (0.35,2.6) 0.9
III 29 2 0.61 (0.15,2.5) 0.5
Smear(baseline)n=606
Positive 257 20 1
Negative 349 47 1.8 (1.1,3.1) 0.022
HIV Status
Negative 370 28 1
Positive 370 50 1.84 (1.2, 2.9) 0.01
CPT(n=133)
No 10 2 1
yes 123 14 0.38 (0.09,1.7) 0.21
ART(n=91)
No 39 7 1
yes 52 9 0.88 (0.33,2.4) 0.8
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been a problem in HIV/TB co- infected).
In the current study, the survival probability is signifi-
cantly lower in HIV positive TB patients; internally
consistent with the earlier finding that significantly
more deaths occurred in HIV positive TB patients. In
addition, when factors such as age, sex, TB type,
baseline weight and age were kept constant, the median
survival probability of HIV positive TB patients would
be within intensive phase and eventually reaches to less
than 15% at the end of continuation phase, while the
survival for HIV negative TB patients remains above
85% throughout the course of DOTS.In keeping with previous studies [17], age, baseline
weight and HIV infection were found to be independent
predictors of [7] death among TB patients on DOTS in
a multivariate adjusted Cox model. Studies showed that
risk of death from TB increases in individuals with weight
loss. Weight loss is a very common phenomena in HIV
(to the extent of being considered as AIDs defining illness)
and TB patients [18].
Weight loss is much pronounced in patients with dual
infection (TB/HIV co infected) compared to HIV negative
TB patients [19]. Consistent with the studies mentioned,
and internally with Cox model, baseline weight was
significantly lower in HIV positive TB patients. AIDs
Table 4 Multivariate cox regression model of factors associated with death of TB patients treated in Hawassa health
center from 2006–2010
Covariates Number at risk Number of deaths Adjusted hazard ratio 95% CI P-value
Residence
Urban 723 75 1
Rural 17 3 1.96 (0 .6, 6.4) 0.26
Gender
Male 417 43 1
Female 323 35 0.87 (0.51, 1.5) 0.61
Age(years) 740 78 1.03 (1.02,1.05) 0.000
Weight(kg) 740 78 0.94 (0.9, 0 .97) 0.000
TB Type
Smear positive PTB 257 20 1
Smear positive PTB 349 47 1.2 (0.68,2.1) 0.53
EPTB 134 11 0.9 (0.4, 1.9) 0.84
HIV Status
Negative 370 28 1
Positive 370 50 1.6 (1.01, 2.6) 0.04
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stantly being sick, from diarrhea that prevents absorption
of nutrients, from loss of appetite and sores of mouth that
make eating difficult and from opportunistic infections.
Similarly, weight loss in TB patients might be explained
partly by the loss of appetite and loss of energy by the
disease itself [20].
Various studies outside Ethiopia have indicated that
the risk of dying from TB increases with the patient's
age. Evidences showed that TB is among the five top
killers of geriatric population. Mortality from TB in
older individuals is attributed to the increased physio-
logic risk of death, to the vague symptoms in the elderly,
diagnostic problems (the problem may be overlooked in
elderly because of other conditions that preoccupy the
attention of physicians) and presence of co-morbidities
and difficulties in accessing diagnosis in this group
of patients, thereby delaying the onset of treatment
[21,22].
In congruence with the above studies, in the present
study, the relative risk of dying from TB increased with
the age of individuals in a dose–response manner in
both the univariate and multivariate analysis.
Apart from such important findings, this study is not
without limitation. As common for secondary data studies,
important variables; CD4 level, ART initiation and CPT
initiation were almost incomplete from the records.
Conclusions
The study demonstrated substantially lower survival
probability for HIV positive TB patients during TB treat-
ment period. The impact of HIV infection was magnifiedduring continuation phase; higher death was demonstrated
in HIV positive TB patients during the self administered
treatment period (continuation phase) compared to HIV
negative TB patients. TB treatment survival of TB patients
is lowered when one is HIV positive, is in an advanced age
category and has low baseline weight.Recommendations
HIV positive TB patients need strict follow up not only
during the intensive phase but also during the continuation
phase. Alongside with the treatment of both infections,
mandatory nutrition counseling should be part and parcel
of TB management in patients with weight loss subsequent
to investigating the possible causes of weight loss. The
management of TB in HIV positive and elderly patients
should be differentiated and comprehensive enough.
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